Jump to content

Search the Community

Showing results for tags 'Side effects'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 26 results

  1. Kezza2

    Now for Docetaxel

    Well gentlemen, The time has come. I was on abiraterone + apelutimide trial for two years until that failed, and swapped to enzalutimide (Xtandi) but that only lasted three months, and now my PSA has more than doubled from 17 to 38 in 6 weeks, so it seems that docetaxel is next on the list. Having not had docetaxel previously I am not a candidate for the Lu177 trial unfortunately, so I am scheduled to start docetaxel in two weeks. I would appreciate any words of wisdom from the wise who have already been through this on side effects and how to avoid or minimise them, and what I may expect.
  2. AnCan 5th Monday Plenary .... Cancer, Sleep & Dreams Tuesday,Jan 30 - Brisbane: Tuesday 30 January 11AM Sydney: Tuesday 30 January Noon Adelaide: Tuesday 30 January 11:30AM Perth: Tuesday 30 January 9AM Joining instructions below pdf attached Hello Friends - One subject we all experience, often in a highly compromised fashion after diagnosis, is SLEEP! It rarely gets addressed ... we just take it for granted even though we spend a third of our lives trying to practice it. How many of you have raised sleep issues with your medical team? How many of you realize many of your side effects are sleep related? AnCan is hosting a rarely addressed topic in our 5th Monday plenary .... 'Cancer & Sleep'. We welcome Dr. Rubin Naiman, a recognized sleep expert who is a colleague of Andrew Weil at the Arizona Integrative Medicine Center. While the presentation addresses all cancers, PCa will get special attention. A pdf is attached and the URL is https://www.ancan.org/cancer-sleep-dreams - this subject impacts most survivors but is all too often swept under the carpet. Please join us and spread the word to others that may be impacted. Questions can be submitted ahead of time to info@ancan.org; or, submitted via the Chat Window if you join online. For phone participants, slides will be available at https://www.ancan.org/cancer-sleep-dreams at least 24 hours prior. If the GoToMeeting Virtual Room is full, please join by phone. Onward & upwards, rick PS Recording should be available within 24 hrs after at https://www.ancan.org/cancer-sleep-dreams JOINING INSTRUCTIONS ONLINE Answer Cancer Meeting Room: Click here or paste https://www.gotomeet.me/AnswerCancer into your browser You will be using your microphone and speakers (VoIP) - to minimize background noise, please mute your mic when not speaking. First GoToMeeting? Do a quick system check: https://link.gotomeeting.com/system-check If the GoToMeeting Virtual Room is full, please join by phone & download slide presentation PHONE United States +1 (646) 749-3129 Canada +1 (647) 497-9353 Australia +61 2 8355 1020 United Kingdom +44 330 221 0088 Access Code: 222-583-973 -- Rick Davis, Founder +1 415 505 0924 rd@ancan.org Next AnCan Women's Breast Cancer Group Feb 1, 2018 - info on website ... spread the word. Next AnCan Men's Breast Cancer Group Feb 22, 2018 - info on website ... spread the word. Answer Cancer Foundation https://www.ancan.org Facebook A Minnesota 501c3 Corp, EIN 81-1588152 6905 Rosemary Road, Eden Prairie MN 55346 If this communication was helpful, please consider a donation! Cancer & Sleep plenary promo final sm.pdf
  3. Prostate Cancer Hormone Therapy Study Have you received hormone therapy treatment for prostate cancer? If so, you may be eligible to join an American Cancer Society funded study to test a program designed to help people with changes to memory, thinking and concentration following hormone therapy for treatment of prostate cancer. This study is done completely over the phone and internet and involves a brief screening to determine eligibility, 3 assessments/interviews, and 8 weeks of home-based computer use. For more information, please contact Lisa Wu at +1 (212) 824-7805 or lisa.wu@mssm.edu This study is approved by the Mount Sinai Institutional Review Board (GCO# 10-1352 approved through 6 April 2015) Dr Lisa Wu is an Instructor in the Department of Oncological Sciences in the Icahn School of Medicine at Mount Sina, New York, one of the leading medical schools in the United States. For a number of years Lisa's work has focused on research into quality of life issues around cancer patients experiencing cognitive difficulties after treatment. Lisa already has a number of men from Australia participating in this study. She is wanting to recruit more Australian men who have had hormone therapy treatment. Given the time difference, sending an email to Lisa is probably the easiest way to make initial contact.
  4. "TAPS stands for “taxane acute pain syndrome”. It is a recognized side effect of treatment with taxanes like docetaxel. It is usually characterized by muscular pain (myalgia) and joint pain (arthralgia) that starts about 24 to 48 hours after taxane treatment and then lasts for up to about 7 days. However, relatively little is known about its incidence and predisposing factors in men with prostate cancer who are being treated with taxane-based chemotherapy..................... The “New” Prostate Cancer InfoLink would suggest that the risk for TAPS is something that needs to be explained to patients prior to their chemotherapy along with guidance about (a) how to address this type of side effect should it occur and (b) the importance of reporting this side effect to their doctors." Click here to read the article from The “New” Prostate Cancer InfoLink.
  5. " In what seems to be a first, study researchers are saying that they might have uncovered a link between ADT and Alzheimer’s. Their study is small and preliminary and it does not prove a cause-and-effect relationship, but merely shows an association between ADT and Alzheimer’s disease." Click here to read more.
  6. Joel Nowak of Malecare reports on an abstract presented at the 2016 American Society of Clinical Oncology (ASCO) Scientific Meeting about how abiraterone (brand name Zytiga) and enzalutamide (brand name Xtandi) may cause cognitive impairment and mood changes. Interestingly the research showed that these side effects were more prevalent with enzalutamide than with abiraterone. Click on this link to read the Malecare report..
  7. Having incurable cancer has caused Larry Axmaker to adjust his definition of "quality of life". Click here to read about how Larry defines "quality of life"
  8. Paul Edwards

    Firmagon injection - minimising side effects

    One of the drugs used in androgen deprivation therapy is Firmagon (degarelix). Firmagon requires a monthly injection. There can be severe pain at the site of the injection (caused by bruising and rashes which can last for 3-4 days each month). This post has been updated with additional suggestions about how to miminise the pain from a Firmagon injection.
  9. We are all familiar with the concept of intermittent ADT as opposed to continuous ADT. Now researchers are investigating the concept of intermittent chemotherapy as opposed to continuous chemotherapy. If certain criteria are met, there will a break in the chemotherapy treatment and the patient will have a “drug holiday”. In theory intermittent chemotherapy may serve 2 purposes. First, with less constant exposure to the drug, this may potentially delay the development of taxane-refractory disease. Second, breaks in therapy or “drug holidays” may improve the quality of life for patients, allowing them to recover from the cumulative toxicity of chemotherapy during these “drug holidays.” Resolution of drug side effects may also allow taxane therapy to be prolonged, which could also improve outcomes. It is interesting to see that one of the abstracts for the 2016 ASCO (American Society of Clinical Oncologists) meeting in Chicago next week is about “PRINCE: A phase III study comparing intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration-resistant prostate cancer”. PRINCE which was a study conducted by German researchers found that: “The intermittent docetaxel chemotherapy was non-inferior to a continuous therapy in one-year survival. It was well tolerated and may present a treatment option for patients with CRPC”. Reference: http://abstract.asco.org/176/AbstView_176_170886.html
  10. Peripheral neuropathy is a common side effect of chemotherapy treatment for prostate cancer. Patients who suffer from this condition have damage to their peripheral nerves and experience weakness, numbness and pain usually in their hands or feet and occasionally in other areas of the body. Researchers at the Moffatt Cancer Center at Tampa, Florida have found that genetic alterations in the VAC14 gene are associated with an increased risk of docetaxel-induced peripheral neuropathy in prostate cancer patients. This discovery may help scientists to understand what causes docetaxel-induced neuropathy and to develop drugs that can reduce peripheral neuropathy.
  11. Depression resulting from Androgen Deprivation Therapy is a completely under-recognized phenomenon, according to a recent article. Click on this link to read the article. Beyond Blue 1300 22 4636 and Lifeline 13 11 14 provide support for depression.
  12. Paul Edwards

    Help! - Hot flushes

    One of our members has just started ADT and complains "These hot flushes are still coming every 30 minutes 24/7. It's nearly 4am and just been woken up again covered in sweat!" What worked for you when you were battling with hot flushes?
  13. ADT carries with it a heightened risk of depression as well as cognitive effects. The cognitive impact, though, is neither well defined nor consistent. The data collectively suggest that the negative impact of ADT on patients directly (and on their intimate partners indirectly) are greater for younger than older men. Across the array of adverse effects, physical exercise appears to have the greatest potential to address the psychological effects of ADT, both in men who are receiving ADT and in their partners. Donovan KA, Walker LM, Wassersug RJ, Thompson LM, Robinson JW. 2015. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer [epub ahead of print] 15 September 2015. www.ncbi.nlm.nih.gov/pubmed/26372364 From Richard Wassersug's Life on ADT Blog
  14. Chemotherapy can cause peripheral neuropathy (damage to your peripheral nerves). Peripheral neuropathy often causes weakness, numbness and pain, usually in your hands and feet. A study of female cancer survivors found that almost half experience chemotherapy-induced peripheral neuropathy symptoms years after completing their cancer treatment. These symptoms were associated with impacts including reduced mobility and significantly increased risk of falls. The results were presented at the American Society of Clinical Oncology (ASCO) Cancer Survivorship Symposium held in San Francisco. The lead researcher said that it is likely that the findings may be applicable to male cancer survivors as well. Click on this link to read the article.
  15. Paul Edwards

    ADT negatively affects mood

    Researchers asked prostate cancer patients to fill in an online questionnaire on their mood in relation to the prostate cancer treatments they had received. Their results showed that, compared to patients not on ADT, ADT does indeed negatively affect the mood of men, most notably increasing their sense of fatigue and decreasing their sense of vigor. The authors also asked partners of patients to rate the patients’ moods. The partners reported similar declines in the patient’s mood that the patients reported, but to a greater degree than the patients themselves. Often our partners know us better than we know ourselves. Van Dam D, Wassersug RJ, Hamilton LD. Androgen deprivation therapy’s impact on the mood of prostate cancer patients as perceived by patients and the partners of patients. Psycho-Oncology 2015; [epub ahead of print] 31 August 2015. www.ncbi.nlm.nih.gov/pubmed/26332203
  16. A retrospective study of nearly 17,000 patients has suggested that androgen-deprivation therapy (ADT) is associated with an increased risk for the future development of Alzheimer's disease in men with prostate cancer,. Click here to read a report in the New Prostate Cancer Infolink about the study. Researchers can’t prove a direct cause-and-effect link between ADT and Alzheimer’s in an observational study like this. Some other unknown variable might be influencing the results........ Given that it’s a first-time association in a retrospective analysis, this study helps inform future research but it’s not appropriate at this point to make treatment decisions off of it......... If your doctor has put you on this medication for your prostate cancer treatment, you should continue it. Consult with your physician, but don’t stop taking your medication based on a study like this....
  17. According to this WebMD paper, for patients prescribed the anticoagulant (blood thinner) warfarin there is a long list of medications that both patient and treating doctor must be aware as causing severe to serious to moderate side effects: http://tinyurl.com/qcafmkw Interesting, among them, are several that prostate cancer patients are prescribed including NSAIDs (identified here http://tinyurl.com/nhtjyvh), enzalutamide, corticosteroids (thus prednisone if prescribed abiraterone), acetaminophen, and several others. If you're a patient prescribed warfarin and also prescribed any of the medications listed, best to discuss with your treating doctor in order to watch diagnostics closely if the combination of these medicines with warfarin is necessary.
  18. I got asked by someone about handling the side effects from chemo. Here are some suggestions. Click on this link for some suggestions from the Cancer Council. Click on this link for a research study which looked at the evidence for what works and what doesn’t. Do any members have other suggestions of what worked for them?
  19. Paul Edwards

    Xofigo Update

    The US Federal Drugs Administration approved the use of Radium 223 (Brand name Xofigo also called Alpharadin) two years ago. The well-known US prostate oncologist Dr Mark Scholz gives an update on the experience of his clinic in using the drug. Click on this link to read his article. Xofigo is not yet available in Australia on the PBS
  20. A good video by the Prostate Cancer Canada Network Calgary. Psychologists from the Tom Baker Cancer Centre in Calgary Canada, Lauren M. Walker and John W. Robinson, share a talk the context of when Androgen Deprivation Therapy, or ADT, is used for treatment. They also talk about the studies and work they've done on the treatment, the side effects and ways to deal with them.
  21. An interesting article about a presentation on hormone therapy made by Australian researchers to this year's American Society of Clinical Oncology (ASCO) Annual Meeting. Click on this link to read it.
  22. The Prostate Cancer Foundation of Australia has posted a video on YouTube of the following talk on Radiation Therapy for Prostate Cancer given by radiation oncologist A/Prof Michael Izard at Sydney Adventist Hospital on 22 June 2015 .
  23. Paul Edwards

    ADT affects the brain

    Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. After chemotherapy treatment it is commonly called "chemo brain." Signs of cognitive impairment include forgetfulness, inability to concentrate, problems recalling information, trouble multi-tasking and becoming slower at processing information. The number of people who experience cognitive problems following cancer therapy is broad, with an estimated range of 15 to 70 percent. There have been several studies analyzing this side effect in breast cancer patients, but few have investigated cognitive impairment following androgen deprivation therapy (ADT) for men being treated prostate cancer. A new Moffitt Cancer Center study indicated that men who are on ADT have greater odds of experiencing impaired cognitive function. In this study, researchers used formal tests to compare the cognitive ability of 58 prostate cancer patients on ADT to 84 prostate cancer patients not on ADT, and to 88 men without cancer. The researchers also reported for the first time a possible genetic link among those individuals who experience cognitive impairment whilst on ADT. They found that patients who have a particular version of a gene called GNB3 were 14 times more likely to suffer from cognitive problems on ADT. The researchers suggested that doctors: before starting ADT, should discuss the risk of changes in cognitive functioning with their patients; and after starting ADT, should also ask their patients if they suffered cognitive impairment with a view to referring them for assessment and treatment as needed. I wrote to one of the researchers and asked what treatment was available for prostate cancer patients on ADT who suffered cognitive impairment as a side effect. This was his reply: “Unfortunately little research has been done on ways to improve cancer treatment-related cognitive impairment. But some recent studies have suggested that "brain training" may improve cognitive function...and [there is] some preliminary evidence suggesting benefits to cancer survivors who had cognitive impairment. There are also medications that could be helpful, such as stimulants (e.g., methylphenidate, modafinil). It is also recommended that other issues that could contribute to cognitive decline be adequately addressed. For example, depression or sleep problems could easily worsen cognitive functioning and are usually treatable. Exercise has also been shown to be very important for cognitive function. I would recommend first addressing the issue with your oncologist or perhaps requesting a referral to a neuropsychologist or another provider who may be able to make recommendations tailored to your situation.” Brian D. Gonzalez et al Course and Predictors of Cognitive Function in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.60.1963
  24. Paul Edwards

    Not having a sex change just yet

    Dr Snuffy Myers suggests that small doses of oestrogen may minimise some of the side effects of Androgen Deprivation Therapy, including, amongst others, cognitive side effects. There were also a few small clinical trials around 2005-2007 which looked at the effect of oestrogen on memory (well-known researcher Tomasz Beer did a couple of these). For some time I've been trying to find someone willing to prescribe me oestrogen for this purpose. Until now, most doctors have been reluctant because of the increased risk of cardiac side effects, particularly deep vein thrombosis. My new endocrinologist was willing to prescribe it. The drug that he prescribed is normally used for transgender patients undergoing a sex change. This led to a very interesting conversation at the chemist when the pharmacist asked me had I used the drug before.
  25. Severe hypocalcemia associated with denosumab (Xgeva or Prolia) in metastatic castration-resistant prostate cancer has been reported on the European Urology website (25/2/2015) Some practice points for physicians have been recommended here. Bone is the most frequent site of metastatic disease in prostate cancer, which can lead to skeletal-related events (SREs) such as pathologic fracture and cord compression. Denosumab is approved by the US Food and Drug Administration (and the TGA / PBS in Australia) for use in solid tumors with bone metastases to prevent or delay SREs such as new fracture and the need for radiotherapy to bone. The authors' case series suggested that a higher prevalence of severe and often prolonged hypocalcemia requiring hospitalization may occur in patients with metastatic castration-resistant prostate cancer in clinical practice. Hypophosphatemia was also commonly identified in cases of severe hypocalcemia. Increased disease burden and vitamin D deficiency were discernible risk factors. Patients with albumin-corrected calcium levels in the low normal range may also be at risk. Hospitalization for aggressive calcium and vitamin D replacement, calcitriol therapy, and correction of other electrolyte imbalances is encouraged for patients who experience severe hypocalcemia while receiving treatment. Denosumab (Xgeva or Prolia) is a unique monoclonal antibody inhibiting 'RANKL', as distinct from zoledronic acid, which is a second generation bisphosphonate, also widely used for bone protection in the context of extended androgen deprivation (ADT) and/or bone metastases. a clinical comparison of these two drugs can be found in this section of The Forum. Patients about to use or already using denosumab should discuss the issues raised above with their prescribing doctors, and should ensure that serum calcium and phosphate are being adequately monitored. Cheers, Alan B
×